New Study Reports Mepolizumab Benefits in Severe Eosinophilic Asthma

Mepolizumab (Nucala) consistently improves exacerbation reduction and asthma control in patients with severe eosinophilic asthma.

New data from the longest anti-ileus 5 (IL-5) biologic therapy trial in severe eosinophilic asthma ever reported has found mepolizumab (Nucala) consistently improves exacerbation reduction and asthma control in patients with the condition.

Data from the open-label COLUMBA study, presented at the 2018 American Thoracic Society (ATS) International Conference in San Diego, CA, reported the results of patients with severe eosinophilic asthma who were treated with mepolizumab for a mean 3.5 years and up to 4.5 years. Along with consistent clinical efficacy, patients treated with the drug reported safety profiles similar with previous studies.

Mepolizumab, from GlaxoSmithKline (GSK), was previously approved by the US Food and Drug Administration (FDA) for the treatment of severe asthma is patients aged 12 years or older who suffer from an eosinophilic phenotype, in November 2015. Last year, it received an expanded indication to treat adults with rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA).

Click to continue reading on MD Magazine.